Correlation Engine 2.0
Clear Search sequence regions


  • celecoxib (3)
  • diclofenac (1)
  • drug antitumor (1)
  • edema (1)
  • humans (1)
  • imatinib (1)
  • imides (6)
  • isozymes (1)
  • oedema (1)
  • PCE 2 (1)
  • rats (1)
  • Sizes of these terms reflect their relevance to your search.

    Cyclic imides containing 3-benzenesulfonamide, oxime, and β-phenylalanine derivatives were synthesised and evaluated to elucidate their in vivo anti-inflammatory and ulcerogenic activity and in vitro cytotoxic effects. Most active anti-inflammatory agents were subjected to in vitro COX-1/2 inhibition assay. 3-Benzenesulfonamides (2-4, and 9), oximes (11-13), and β-phenylalanine derivative (18) showed potential anti-inflammatory activities with 71.2-82.9% oedema inhibition relative to celecoxib and diclofenac (85.6 and 83.4%, respectively). Most active cyclic imides 4, 9, 12, 13, and 18 possessed ED50 of 35.4-45.3 mg kg-1 relative to that of celecoxib (34.1 mg kg-1). For the cytotoxic evaluation, the selected derivatives 2-6 and 8 exhibited weak positive cytotoxic effects (PCE = 2/59-5/59) at 10 μM compared to the standard drug, imatinib (PCE = 20/59). Cyclic imides bearing 3-benzenesulfonamide (2-5, and 9), acetophenone oxime (11-14, 18, and 19) exhibited high selectivity against COX-2 with SI > 55.6-333.3 relative to that for celecoxib [SI > 387.6]. β-Phenylalanine derivatives 21-24 and 28 were non-selective towards COX-1/2 isozymes as indicated by their SI of 0.46-0.68.

    Citation

    Alaa A-M Abdel-Aziz, Adel S El-Azab, Nawaf A AlSaif, Mohammed M Alanazi, Manal A El-Gendy, Ahmad J Obaidullah, Hamad M Alkahtani, Abdulrahman A Almehizia, Ibrahim A Al-Suwaidan. Synthesis, anti-inflammatory, cytotoxic, and COX-1/2 inhibitory activities of cyclic imides bearing 3-benzenesulfonamide, oxime, and β-phenylalanine scaffolds: a molecular docking study. Journal of enzyme inhibition and medicinal chemistry. 2020 Dec;35(1):610-621

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 32013633

    View Full Text